A Phase II Study of Pemetrexed in Children withRecurrent Malignancies

Eli Lilly and Company0 个研究点目标入组 80 人开始时间: 2017年3月2日最近更新: 2017年4月3日

适应症

试验速览

暂无简介。

•Patients must have osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma
•Measurable disease
•Eastern Cooperative Oncology Group (ECOG) performance 0,1,2
•Adequate renal, liver and bone marrow function
•Patient's current disease state must be one with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 57
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Growth factors that support platelet or white cell number or function must not have been administered within the last 7 days prior to enrollment (14 days if Neulasta)
•Patients with central nervous system (CNS) tumors who have not been on a stable or decreasing dose of dexamethasone or other corticosteroid for 7 days prior to enrollment
•Patients with uncontrolled infection
•Patients who have received pemetrexed previously
•Patients with pleural effusions or ascites

发起方